Back to News
Market Impact: 0.3
Roche Gets FDA Filing Acceptance For Fenebrutinib In MS; Launches Newborn Screening Test
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Roche said the FDA accepted its New Drug Application for fenebrutinib in relapsing multiple sclerosis and primary progressive multiple sclerosis under Priority Review. The accelerated regulatory review is a positive milestone for Roche's neurology pipeline, though approval and commercialization outcomes remain pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.40
More News
- Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
- US judge approves settlement allowing Paramount to acquire Warner Bros
- Why is Nidec stock plunging today?
- California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto
- Google rolls out Gemini 4 Argon, its most advanced AI model
- Meta stock enjoys best month since 2022 on AI momentum